DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04428775 (ClinicalTrials.gov)	September 8, 2020	3/6/2020	A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease	A Phase IIa, Randomized, Open-label, Multi-Center, Multi-Dose Study to Evaluate the Effects of ALZT-OP1a in Subjects With Mild-Moderate Stage Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: ALZT-OP1a (cromolyn)	AZTherapies, Inc.	NULL	Recruiting	18 Years	75 Years	All	80	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04428775
(ClinicalTrials.gov)

September 8, 2020

3/6/2020

A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease

A Phase IIa, Randomized, Open-label, Multi-Center, Multi-Dose Study to Evaluate the Effects of ALZT-OP1a in Subjects With Mild-Moderate Stage Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Drug: ALZT-OP1a (cromolyn)

AZTherapies, Inc.

NULL

Recruiting

18 Years

75 Years

All

Phase 2

United States